Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 22 | 2022 | 1103 | 3.930 |
Why?
|
| Exercise | 15 | 2023 | 613 | 3.330 |
Why?
|
| Exercise Therapy | 11 | 2019 | 69 | 2.960 |
Why?
|
| Quality of Life | 13 | 2022 | 481 | 2.850 |
Why?
|
| Survivors | 15 | 2022 | 136 | 2.680 |
Why?
|
| Indians, North American | 6 | 2022 | 159 | 2.580 |
Why?
|
| Fatigue | 9 | 2022 | 83 | 2.230 |
Why?
|
| Resistance Training | 5 | 2015 | 18 | 1.670 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2021 | 28 | 1.590 |
Why?
|
| Health Promotion | 5 | 2023 | 653 | 1.380 |
Why?
|
| Muscle Strength | 4 | 2015 | 29 | 1.310 |
Why?
|
| Middle Aged | 25 | 2022 | 10129 | 1.020 |
Why?
|
| Breast Neoplasms | 7 | 2012 | 1502 | 1.020 |
Why?
|
| Lung Neoplasms | 4 | 2017 | 358 | 1.010 |
Why?
|
| Antineoplastic Agents | 5 | 2021 | 803 | 0.950 |
Why?
|
| Aged | 18 | 2022 | 6741 | 0.940 |
Why?
|
| Humans | 49 | 2023 | 37093 | 0.890 |
Why?
|
| Bone Density | 4 | 2012 | 75 | 0.870 |
Why?
|
| Focus Groups | 2 | 2022 | 348 | 0.800 |
Why?
|
| Female | 28 | 2022 | 20969 | 0.770 |
Why?
|
| Athletic Injuries | 1 | 2021 | 22 | 0.770 |
Why?
|
| Sports | 1 | 2021 | 48 | 0.750 |
Why?
|
| Treatment Outcome | 11 | 2022 | 1369 | 0.700 |
Why?
|
| Costs and Cost Analysis | 1 | 2019 | 57 | 0.690 |
Why?
|
| Community-Based Participatory Research | 3 | 2019 | 317 | 0.680 |
Why?
|
| Patients | 1 | 2017 | 14 | 0.610 |
Why?
|
| Women's Health | 2 | 2015 | 145 | 0.580 |
Why?
|
| Caregivers | 1 | 2019 | 182 | 0.580 |
Why?
|
| Male | 18 | 2022 | 20025 | 0.570 |
Why?
|
| Adult | 16 | 2022 | 11712 | 0.570 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 88 | 0.560 |
Why?
|
| Exercise Tolerance | 2 | 2019 | 15 | 0.550 |
Why?
|
| Confidentiality | 1 | 2016 | 26 | 0.550 |
Why?
|
| Information Dissemination | 1 | 2016 | 59 | 0.540 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2015 | 13 | 0.520 |
Why?
|
| Reproductive History | 1 | 2015 | 19 | 0.520 |
Why?
|
| Data Collection | 1 | 2016 | 194 | 0.520 |
Why?
|
| Cooperative Behavior | 2 | 2018 | 219 | 0.520 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2015 | 44 | 0.520 |
Why?
|
| Community-Institutional Relations | 2 | 2018 | 187 | 0.510 |
Why?
|
| Rest | 1 | 2015 | 26 | 0.510 |
Why?
|
| Physical Therapy Modalities | 1 | 2015 | 32 | 0.490 |
Why?
|
| Postmenopause | 2 | 2012 | 128 | 0.490 |
Why?
|
| Osteoporosis | 2 | 2012 | 34 | 0.480 |
Why?
|
| Depression | 2 | 2019 | 712 | 0.460 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 404 | 0.460 |
Why?
|
| Anxiety | 2 | 2019 | 754 | 0.450 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 560 | 0.440 |
Why?
|
| Hip Fractures | 1 | 2012 | 23 | 0.410 |
Why?
|
| Risk Factors | 6 | 2021 | 3562 | 0.410 |
Why?
|
| Pilot Projects | 4 | 2022 | 661 | 0.400 |
Why?
|
| Hand Strength | 1 | 2011 | 34 | 0.400 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2011 | 21 | 0.390 |
Why?
|
| Practice Guidelines as Topic | 5 | 2012 | 191 | 0.380 |
Why?
|
| Motor Activity | 2 | 2012 | 418 | 0.350 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 2379 | 0.300 |
Why?
|
| Methylphenidate | 2 | 2009 | 55 | 0.290 |
Why?
|
| Arizona | 2 | 2018 | 100 | 0.290 |
Why?
|
| Young Adult | 3 | 2022 | 4268 | 0.280 |
Why?
|
| Qualitative Research | 2 | 2020 | 446 | 0.280 |
Why?
|
| Physical Fitness | 2 | 2019 | 90 | 0.270 |
Why?
|
| Cohort Studies | 2 | 2020 | 1492 | 0.260 |
Why?
|
| Central Nervous System Stimulants | 2 | 2009 | 174 | 0.260 |
Why?
|
| Prospective Studies | 4 | 2019 | 1378 | 0.240 |
Why?
|
| Michigan | 2 | 2023 | 22 | 0.240 |
Why?
|
| Life Style | 2 | 2020 | 308 | 0.230 |
Why?
|
| Program Evaluation | 2 | 2022 | 339 | 0.220 |
Why?
|
| Interferon-alpha | 1 | 2002 | 43 | 0.210 |
Why?
|
| Marijuana Abuse | 1 | 2023 | 91 | 0.210 |
Why?
|
| Cultural Competency | 1 | 2022 | 131 | 0.200 |
Why?
|
| Melanoma | 1 | 2002 | 96 | 0.190 |
Why?
|
| Neoplasm Staging | 2 | 2012 | 275 | 0.190 |
Why?
|
| Activities of Daily Living | 2 | 2015 | 105 | 0.190 |
Why?
|
| Patient Compliance | 2 | 2015 | 212 | 0.190 |
Why?
|
| Athletes | 1 | 2021 | 56 | 0.190 |
Why?
|
| Adaptation, Physiological | 1 | 2021 | 109 | 0.190 |
Why?
|
| Mental Health | 1 | 2004 | 303 | 0.180 |
Why?
|
| Housing | 1 | 2020 | 59 | 0.180 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2019 | 7 | 0.170 |
Why?
|
| Research Personnel | 2 | 2021 | 155 | 0.170 |
Why?
|
| Walking | 2 | 2021 | 68 | 0.170 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2019 | 35 | 0.170 |
Why?
|
| Employment | 1 | 2019 | 76 | 0.170 |
Why?
|
| Perception | 1 | 2020 | 195 | 0.160 |
Why?
|
| Pain | 1 | 2021 | 251 | 0.160 |
Why?
|
| Smoking | 2 | 2015 | 940 | 0.160 |
Why?
|
| Health Behavior | 1 | 2022 | 537 | 0.150 |
Why?
|
| Resilience, Psychological | 1 | 2019 | 66 | 0.150 |
Why?
|
| Residence Characteristics | 2 | 2021 | 322 | 0.150 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 54 | 0.150 |
Why?
|
| Patient Education as Topic | 2 | 2009 | 215 | 0.150 |
Why?
|
| Evidence-Based Medicine | 3 | 2019 | 97 | 0.140 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 198 | 0.140 |
Why?
|
| Prognosis | 3 | 2019 | 739 | 0.140 |
Why?
|
| Privacy | 1 | 2016 | 7 | 0.140 |
Why?
|
| Bioethical Issues | 1 | 2016 | 6 | 0.140 |
Why?
|
| Health Personnel | 1 | 2019 | 228 | 0.140 |
Why?
|
| Severity of Illness Index | 3 | 2012 | 610 | 0.140 |
Why?
|
| Registries | 1 | 2017 | 335 | 0.130 |
Why?
|
| American Cancer Society | 2 | 2012 | 3 | 0.130 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 312 | 0.130 |
Why?
|
| Feedback | 1 | 2015 | 53 | 0.120 |
Why?
|
| Attitude to Health | 1 | 2017 | 325 | 0.120 |
Why?
|
| Vulnerable Populations | 1 | 2016 | 140 | 0.120 |
Why?
|
| Receptors, Nicotinic | 1 | 2015 | 106 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 204 | 0.120 |
Why?
|
| United States | 4 | 2021 | 4223 | 0.120 |
Why?
|
| Community Health Services | 1 | 2015 | 185 | 0.110 |
Why?
|
| Educational Status | 1 | 2014 | 313 | 0.110 |
Why?
|
| Mutation | 1 | 2017 | 1095 | 0.110 |
Why?
|
| Nerve Tissue Proteins | 1 | 2015 | 360 | 0.110 |
Why?
|
| Hip Joint | 1 | 2012 | 13 | 0.100 |
Why?
|
| Single-Blind Method | 1 | 2011 | 55 | 0.100 |
Why?
|
| Body Mass Index | 2 | 2021 | 854 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2012 | 37 | 0.100 |
Why?
|
| Age Distribution | 1 | 2012 | 225 | 0.100 |
Why?
|
| Survival Rate | 2 | 2012 | 311 | 0.100 |
Why?
|
| Nutritional Status | 1 | 2012 | 116 | 0.100 |
Why?
|
| Body Weights and Measures | 1 | 2011 | 22 | 0.100 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 127 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 400 | 0.090 |
Why?
|
| Faculty | 2 | 2021 | 94 | 0.090 |
Why?
|
| Bone Remodeling | 1 | 2010 | 9 | 0.090 |
Why?
|
| Heart | 1 | 2012 | 180 | 0.090 |
Why?
|
| Longitudinal Studies | 2 | 2012 | 885 | 0.090 |
Why?
|
| Dietary Supplements | 2 | 2012 | 208 | 0.090 |
Why?
|
| Mentors | 2 | 2021 | 127 | 0.090 |
Why?
|
| Nursing Assessment | 1 | 2009 | 6 | 0.090 |
Why?
|
| Absorptiometry, Photon | 1 | 2009 | 75 | 0.090 |
Why?
|
| Nursing Evaluation Research | 1 | 2008 | 12 | 0.080 |
Why?
|
| Smoking Cessation | 1 | 2015 | 517 | 0.080 |
Why?
|
| Body Composition | 1 | 2009 | 162 | 0.080 |
Why?
|
| Nurse's Role | 1 | 2008 | 31 | 0.080 |
Why?
|
| Weight Gain | 1 | 2009 | 136 | 0.080 |
Why?
|
| Valerates | 1 | 2008 | 2 | 0.080 |
Why?
|
| Cachexia | 1 | 2008 | 6 | 0.080 |
Why?
|
| Adipose Tissue | 1 | 2009 | 177 | 0.080 |
Why?
|
| Glutamine | 1 | 2008 | 40 | 0.080 |
Why?
|
| Forecasting | 1 | 2008 | 128 | 0.080 |
Why?
|
| Arginine | 1 | 2008 | 73 | 0.080 |
Why?
|
| Methotrexate | 1 | 2007 | 23 | 0.070 |
Why?
|
| Health Services Needs and Demand | 1 | 2008 | 146 | 0.070 |
Why?
|
| Aging | 1 | 2012 | 664 | 0.070 |
Why?
|
| Menopause | 1 | 2007 | 56 | 0.070 |
Why?
|
| Glucocorticoids | 1 | 2007 | 86 | 0.070 |
Why?
|
| Doxorubicin | 1 | 2007 | 84 | 0.070 |
Why?
|
| Research Design | 1 | 2008 | 313 | 0.070 |
Why?
|
| Adaptation, Psychological | 1 | 2009 | 385 | 0.070 |
Why?
|
| Algorithms | 1 | 2009 | 465 | 0.070 |
Why?
|
| Minority Groups | 2 | 2021 | 596 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 664 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 182 | 0.060 |
Why?
|
| Age Factors | 1 | 2008 | 1033 | 0.060 |
Why?
|
| Health Status | 1 | 2008 | 380 | 0.060 |
Why?
|
| Physical Education and Training | 1 | 2023 | 28 | 0.060 |
Why?
|
| Memory, Short-Term | 1 | 2023 | 49 | 0.060 |
Why?
|
| Social Behavior | 1 | 2004 | 131 | 0.050 |
Why?
|
| Cancer Care Facilities | 1 | 2002 | 17 | 0.050 |
Why?
|
| School Health Services | 1 | 2023 | 81 | 0.050 |
Why?
|
| Environment Design | 1 | 2021 | 24 | 0.050 |
Why?
|
| Health Policy | 1 | 2023 | 165 | 0.050 |
Why?
|
| Schools | 1 | 2023 | 260 | 0.050 |
Why?
|
| Incidence | 2 | 2014 | 922 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2008 | 2721 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2002 | 550 | 0.050 |
Why?
|
| Lymphedema | 1 | 2019 | 8 | 0.040 |
Why?
|
| Psychometrics | 1 | 2002 | 318 | 0.040 |
Why?
|
| Exercise Test | 1 | 2019 | 67 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 20 | 0.040 |
Why?
|
| Cognition | 1 | 2002 | 398 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2018 | 80 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2019 | 95 | 0.040 |
Why?
|
| Trust | 1 | 2018 | 133 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 893 | 0.040 |
Why?
|
| Decision Making | 1 | 2018 | 203 | 0.040 |
Why?
|
| Child | 1 | 2004 | 3131 | 0.030 |
Why?
|
| North America | 1 | 2014 | 67 | 0.030 |
Why?
|
| Asia | 1 | 2014 | 75 | 0.030 |
Why?
|
| Europe | 1 | 2014 | 101 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2012 | 16 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2015 | 387 | 0.030 |
Why?
|
| Adolescent | 1 | 2023 | 5363 | 0.030 |
Why?
|
| Prescriptions | 1 | 2012 | 18 | 0.030 |
Why?
|
| Phenotype | 1 | 2015 | 689 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2012 | 42 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 148 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2012 | 59 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2012 | 117 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 1130 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 1067 | 0.020 |
Why?
|
| Time Factors | 1 | 2015 | 1742 | 0.020 |
Why?
|
| Fractures, Bone | 1 | 2010 | 53 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2012 | 753 | 0.020 |
Why?
|
| Plethysmography | 1 | 2008 | 6 | 0.020 |
Why?
|
| Placebos | 1 | 2008 | 37 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2008 | 88 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 108 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2008 | 286 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 227 | 0.020 |
Why?
|